Abbott Laboratories' (NYSE:ABT) stock up by 8.7% over the past three months. Since the market usually pay for a company’s long-term financial health, we decided to study the company’s fundamentals to ...

In the latest market close, Abbott (ABT) reached $113.70, with a -0.39% movement compared to the previous day. This move lagged the S&P 500's daily loss of 0.19%. Meanwhile, the Dow experienced a rise ...

The fragility of the infant formula market is being tested again — this time by legal fights over safety labeling. The big ...

A lawsuit against Yale New Haven Hospital and Yale University, accusing them of wrongful death for giving a premature baby ...

Inflated jury verdicts in the first two preterm infant formula cases tried in the country have raised significant concerns for manufacturers and ...

In a lawsuit, a Meriden woman says her premature baby was sickened and died after being given cow's milk formula without her ...

The use of an oral nutrition supplement for over six months has shown improvements in protein, calcium, and vitamin B12 ...

Piper Sandler initiated coverage on Abbott Laboratories (NYSE:ABT) with an "overweight" rating and a price target of $131 per ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

The lawsuits allege that the companies failed to adequately warn healthcare providers of increased disease risks when using their infant formula. These are the recent developments for Abbott ...